gdc
Multiple Myeloma

Patient Education and Oral Medications

Gary Peterson discusses the need for patients to be well-informed about their oral medications and asserts that there is a huge opportunity to improve patient education.
Video Library – December 7, 2015
Gary Petersen

Of course they're different for oral versus administered by the doctor. The reason is it's because when they're administered by the doctor, the doctor has a schedule. He's going to provide that. He's going to be there to make sure the patient in fact takes it.

With regard to oral, it's the same two things that affect it here that I mentioned in the previous one. People, who are of that age and have chemo brain, are likely to forget it a few times. Heck, they might forget it for a couple of days. There's got to be a way to prevent that from happening.

The second thing is that, if in fact they only have a certain amount of money to pay for their drugs, they may choose to ration their drugs, even knowing that they'll be far less effective.

You may go through the whole educational process, which I think there should be an educational process, to tell them how important it is, and that you can't skimp, but when it comes right down to it, it's all about the money.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country